// App-Quantinova.ai

5035 : Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa).

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Rebecca J Nagy

  • Neeraj Agarwal

  • Theodore Stewart Gourdin

  • Gurudatta Naik

  • Shahrooz Eshaghian

  • Jue Wang

  • Andrew J. Armstrong

  • Ulka N. Vaishampayan

  • Petros Grivas

  • Sumanta K. Pal

  • Richard Burnham Lanman

  • Amirali Talasaz

  • Michael B. Lilly

Medical Centers

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Guardant Health, Rewdwood City, CA

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • University of Alabama at Birmingham, Birmingham, AL

  • Compassionate Hem and Onc, Los Angeles, CA

  • University of Arizona Cancer Center at DH-SJHMC, Phoenix, AZ

  • Duke Cancer Institute, Durham, NC

  • Karmanos Cancer Institute, Detroit, MI

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • City of Hope, Duarte, CA

  • Medcl Univ of South Carolina, Charleston, SC

Locations

  • United States

Companies

  • Guardant Health, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved